Format

Send to

Choose Destination
JCI Insight. 2018 Mar 8;3(5). pii: 98960. doi: 10.1172/jci.insight.98960.

Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.

Author information

1
Intensive Care Unit, and.
2
Inserm CIC-1435, Dupuytren University Hospital, Limoges, France.
3
Inserm UMR-1092, University of Limoges, Limoges, France.
4
Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA.
5
Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, USA.
6
Cellular Immunology Laboratory, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.
7
EA 7426 PI3 "Pathophysiology of Injury-induced Immunosuppression", Université Claude Bernard Lyon I-Biomérieux-Hospices Civils de Lyon, Lyon, France.
8
Anesthesiology and Intensive Care Medicine, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.
9
Revimmune SAS, Paris, France.
10
Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
11
Cytokines and Immunity Section, National Cancer Institute, Bethesda, Maryland, USA.
12
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
13
Department of Medicine, and.
14
Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.

Abstract

BACKGROUND:

A defining pathophysiologic feature of sepsis is profound apoptosis-induced death and depletion of CD4+ and CD8+ T cells. Interleukin-7 (IL-7) is an antiapoptotic common γ-chain cytokine that is essential for lymphocyte proliferation and survival. Clinical trials of IL-7 in over 390 oncologic and lymphopenic patients showed that IL-7 was safe, invariably increased CD4+ and CD8+ lymphocyte counts, and improved immunity.

METHODS:

We conducted a prospective, randomized, double-blind, placebo-controlled trial of recombinant human IL-7 (CYT107) in patients with septic shock and severe lymphopenia. Twenty-seven patients at academic sites in France and the United States received CYT107 or placebo for 4 weeks. Primary aims were to determine the safety of CYT107 in sepsis and its ability to reverse lymphopenia.

RESULTS:

CYT107 was well tolerated without evidence of inducing cytokine storm or worsening inflammation or organ dysfunction. CYT107 caused a 3- to 4-fold increase in absolute lymphocyte counts and in circulating CD4+ and CD8+ T cells that persisted for weeks after drug administration. CYT107 also increased T cell proliferation and activation.

CONCLUSIONS:

This is the first trial of an immunoadjuvant therapy targeting defects in adaptive immunity in patients with sepsis. CYT107 reversed the marked loss of CD4+ and CD8+ immune effector cells, a hallmark of sepsis and a likely key mechanism in its morbidity and mortality. CYT107 represents a potential new way forward in the treatment of patients with sepsis by restoring adaptive immunity. Such immune-based therapy should be broadly protective against diverse pathogens including multidrug resistant bacteria that preferentially target patients with impaired immunity.

TRIAL REGISTRATION:

Trials registered at clinicaltrials.gov: NCT02640807 and NCT02797431.

FUNDING:

Revimmune, NIH National Institute of General Medical Sciences GM44118.

KEYWORDS:

Immunology; T cells

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center